Plaque psoriasis is a well-known, chronic, progressive, inflammatory disease that is associated with comorbidities, high economic burden and sequelae that impacts multiple aspects of patients’ lives. In recent decades, there has been significant clinical advancement in the treatments for moderate to severe plaque psoriasis with diverse modes of administration and mechanisms of action.

Despite the emergence of newer therapies, there remains an unmet need in psoriasis patients. Payers look to understand the goals for improving the standard of care and the value of treatments in the real-world beyond the outcomes achieved in clinical trials. There is an evolving treatment paradigm that models high levels of clinical disease improvement, lowers the economic burden of psoriasis and may reduce the patients’ risk for comorbid conditions.

Learning Objectives

• Understand the associated medical conditions of psoriasis and how the disease can affect multiple aspects of patients' lives.
• Review the treatment targets for psoriasis and the unmet need in current treatment options.
• Discuss the impact of the evolving treatment paradigm for plaque psoriasis and optimal characteristics of advanced therapies.

Alopecia Areata can occur in patients at any age and often has an unpredictable course. Up to 1 in 4 patients with alopecia areata are at risk of developing alopecia totalis or alopecia universalis. For patients with alopecia areata, there remains a need for more treatment options. Alopecia areata is a systemic autoimmune disease with an underlying immuno-inflammatory pathogenesis.  This sponsored webinar provides an overview of the impact and burden on patients with severe alopecia areata, an introduction to a new treatment option including initiation and monitoring, and the consideration of appropriate patients for treatment.

This sponsored webinar provides disease education for population-based decision makers to enhance their understanding of current food allergy management practices, the unmet needs in management of food allergies, and the impact of food allergies at multiple levels.

Learning Objectives:

• Differentiate between food allergies and food intolerances, and the diagnostic issues involved
• Review of food allergy management approaches
• Highlight the various socioeconomic impacts with their aggregate monetary and human costs to patients and the healthcare system

Join AMCP Foundation for this National P&T Competition Training webinar. Our content expert will share best practices that managed care professionals would follow when developing drug monographs. If you're planning to participate in the 2024 P&T Competition, you don't want to miss these insights! This webinar will be hosted live on Zoom, with an opportunity to pose questions at the end of the presentation. A recorded version of the webinar will be posted on the AMCP Foundation website within 10 days of the live program. Competitors, student pharmacists, and all interested individuals are welcome to register.

Urinary tract infections (UTIs) are among the most common bacterial infections encountered in the ambulatory care setting in the United States. Rates of E. Coli resistance to some commonly prescribed treatments for community-acquired uncomplicated UTIs are high in some regions in the US, attributing to treatment failure. Recent evidence has shown that approximately 12% to 17% of patients diagnosed with an uncomplicated UTI experienced failure to empiric treatment for various reasons. Understanding those factors that may place a patient at higher risk of treatment failure can help to guide appropriate treatment. This program will provide disease education for population-based decision makers to inform on AMR in uncomplicated UTI, risk of treatment failure, and clinical and economic consequences of treatment failure.

Learning Objectives:

• Define uncomplicated UTI and review current management
• Inform on rates of antimicrobial resistance to common pathogens in community-acquired uncomplicated UTI
• Describe risk factors for treatment failure in uncomplicated UTI and clinical and economic consequences of failure
• Discuss how antimicrobial stewardship is an important part of addressing AMR challenges

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Elevar Therapeutics.

You are invited to attend a virtual PIE webinar about a new investigational treatment for unresectable or metastatic hepatocellular carcinoma (uHCC): Rivoceranib + Camrelizumab.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

This non-promotional, sponsored webinar will review health plan best practice recommendations for Chronic Lymphocytic Leukemia (CLL) with an impressive panel of oncology and managed care experts.

As managed care and payer professionals play a central role in improving value in and access to cancer care, understanding best practices in CLL that address the multidimensional system challenges can support identifying which health services are safe, efficacious, and cost-effective, address barriers to high-quality care, and better understand the patient experience in the health care system.

In this webinar, a panel of experts will discuss health plan best practices related to CLL, national managed care oncology professional survey results, and components of high-quality care that can improve health equity and address unmet needs in CLL. Following the presentation, join the panelists for a live Q&A session.

In this webinar, a panel of experts discuss health plan best practices related to continuous glucose monitoring. Following the presentation, join the panelists for a live Q&A session.

Learn About:

At the completion of this activity, participants should be able to:

• Explore health plan practices for the treatment of CLL
• Discuss key insights from a national managed care oncology survey on the treatments for CLL
• Examine strategies available to managed care professionals to guide treatment for CLL
• Identify components of high-quality care that improve health equity and address unmet needs in cancer care